Ceredex Value Advisors LLC Acquires Shares of 213,450 Bruker Corporation $BRKR

Ceredex Value Advisors LLC bought a new position in shares of Bruker Corporation (NASDAQ:BRKR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 213,450 shares of the medical research company’s stock, valued at approximately $12,845,000. Ceredex Value Advisors LLC owned about 0.14% of Bruker as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Orbis Allan Gray Ltd grew its holdings in Bruker by 5.4% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,906,730 shares of the medical research company’s stock worth $702,256,000 after acquiring an additional 761,258 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Bruker in the second quarter worth about $570,746,000. State Street Corp raised its stake in shares of Bruker by 2.5% in the fourth quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after acquiring an additional 91,706 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. Finally, Sculptor Capital LP grew its stake in shares of Bruker by 9.0% during the first quarter. Sculptor Capital LP now owns 3,270,000 shares of the medical research company’s stock valued at $118,112,000 after purchasing an additional 270,000 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Trading Up 2.2%

Shares of NASDAQ BRKR opened at $59.92 on Friday. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $65.30. The firm has a market capitalization of $9.13 billion, a P/E ratio of -85.60, a P/E/G ratio of 1.79 and a beta of 1.28. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The company’s 50 day simple moving average is $58.55 and its 200 day simple moving average is $47.39.

Bruker (NASDAQ:BRKR) last issued its earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, analysts predict that Bruker Corporation will post 2.12 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio is currently -28.57%.

Wall Street Analyst Weigh In

Several research firms have issued reports on BRKR. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Stifel Nicolaus set a $50.00 target price on Bruker in a research note on Wednesday, August 5th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Wolfe Research started coverage on Bruker in a research note on Monday, June 1st. They set a “peer perform” rating on the stock. Finally, JPMorgan Chase & Co. raised their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $56.64.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.